RMAM
CLDX icon

Raab & Moskowitz Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-66
Closed – – 201
2019
Q4 		$0 Buy
+66
New +$153 ﹤0.01% 538
2018
Q4 		– Sell
-67
Closed – – 217
2018
Q3 		$0 Buy
+67
New +$469 ﹤0.01% 541

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Raab & Moskowitz Asset Management's CLDX Position: Q1 2020 in Review

Raab & Moskowitz Asset Management sold out of Celldex Therapeutics (CLDX) in Q1 2020, closing a stake of 66 shares.

Raab & Moskowitz Asset Management first reported a position in CLDX in Q3 2018 and held it in 2 quarters. The position peaked at $0 in Q4 2019. 45 funds tracked by Wall St. Rank hold CLDX as of Q1 2020.

  • Raab & Moskowitz Asset Management reported no remaining Celldex Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Raab & Moskowitz Asset Management sold 66 Celldex Therapeutics shares in Q1 2020.
  • Raab & Moskowitz Asset Management first reported a position in Celldex Therapeutics in Q3 2018 and held it in 2 quarters.
  • Raab & Moskowitz Asset Management's Celldex Therapeutics position peaked at $0 in Q4 2019.
  • 45 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2020.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2020, filed 14 May 2020.